Skip to main content

New story in Health from Time: Moderna Plans To Start Phase 3 Testing of its COVID-19 Vaccine Candidate in July



On June 11, biotech company Moderna announced it had finalized plans for phase 3 testing of its COVID-19 vaccine candidate. The late-stage trial will include 30,000 participants and is expected to begin in July.

The trial will test just one dose level of the vaccine, 100 micrograms, given in two shots. In the earlier phase 1 study involving 45 healthy volunteers, the company explored lower and higher doses, but preliminary results revealed by the company from this trial suggested that 100 micrograms provided the desired immune response safely. According to the company, the vaccine produced antibodies against the COVID-19 virus in those who were vaccinated, and in tests involving a handful of participants, those antibodies were able to neutralize the virus in the lab. The full details of that study aren’t available yet; that will soon be published by Moderna’s collaborators, a team of scientists at the National Institute of Allergy and Infectious Diseases.

The phase 2 study is ongoing, and is enrolling 600 healthy people who will be followed for a year after their injections. This stage will continue to look at the vaccine’s safety as well as collect further data on its effectiveness. This study will include more people who might be a high risk of exposure to COVID-19, such as health care workers and residents in long-term care facilities.

In June, Moderna became one of five vaccine developers chosen to be part of President Trump’s Operation Warp Speed program to speed development of a COVID-19 vaccine. The selection qualifies Moderna to receive federal government funding to continue development of vaccine, conduct tests, as well as scale up manufacturing to meet the goal of beginning to inoculate 300 million people beginning early next year. Moderna said it plans to deliver 500 million to 1 billion doses a year beginning in 2021.

Popular posts from this blog

New story in Health from Time: COVID-19 Has Been ‘Apocalyptic’ for Public Transit. Will Congress Offer More Help?

While trying to get to work over the past few months, Brittany Williams, a Seattle home care worker, has often been passed by two or three buses before one stops to let her board. Buses in her area that once carried anywhere from about 50 to 100 passengers have been limited to between 12 and 18 to prevent overcrowding in response to coronavirus, and Williams’ commute, typically a half-hour ride, now takes more than double that time. Other Seattle transit riders have described budgeting as much as an extra hour per trip to account for the reduced capacity, eating into their time at work, school or with family. Even with the ridership limits in place, Williams, 34, doesn’t feel safe on public transit. Some passengers don’t wear face coverings, and bus drivers sometimes ignore capacity limits, she says. On one ride with her seven-year-old son, she decided to get off at a stop far from her home after a driver allowed a crowd of people to board. “It’s very trying. I’ll put...

New story in Health from Time: An At-Home Coronavirus Test May Be On the Way in the U.S.

As cases of COVID-19 continue to climb in the U.S. , there’s a new urgency to make sure there are as many tests as possible to diagnose people who have symptoms that might indicate an infection. Knowing if people are positive is important for guiding their next steps: self-isolation, avoiding contact with others, and, if their symptoms get worse, seeking medical care. To date, access to tests has been spotty at best across the country, and while more kits are now available than even a week ago , most are gene-based assays that take several days for commercial labs to process and produce results. That may change in about two months if the Food and Drug Administration (FDA) gives Emergency Use Authorization to the first blood-based COVID-19 test in the U.S. Scanwell Health, an at-home test company based in California, licensed the rights to a test developed by Chinese company Innovita, which was used extensively at the height of country’s epidemic earlier this year. “The ...

New story in Health from Time: AFM, a Biennial Polio-Like Viral Illness, Is Expected to Hit the U.S. in 2020

Nobody foresaw the COVID-19 curveball nature was going to throw at us 2020—which is one of the reasons the world has had so much trouble ducking the pitch. But we’ve know for years that another disease, known as acute flaccid myelitis (AFM), would hit hard this year—beginning this month, in fact. The U.S. Centers for Disease Control and Prevention (CDC) today held a media teleconference and issued a Vital Signs report reminding families that the illness is fast-approaching, and that in a time of pandemic there could be particular challenges in responding to it that would not be present in other years. AFM is a paralytic condition that is not polio—but not dissimilar to polio either. It strikes mostly children (the average age is 5); it is caused by a virus (likely an enterovirus, a type that incubates in the gut); and worst of all, it can lead to paralysis of the limbs, face and diaphragm, sometimes resulting in death. Like polio, AFM is seasonal, though its peak is Augus...